US FDA OKs Lilly, Daiichi's Effient blood thinner
WASHINGTON, July 10 (Reuters) - The U.S. Food and Drug Administration has approved Eli Lilly and Co (LLY.N) and Daiichi Sankyo Co Ltd's (4568.T) long-awaited bloodthinner Effient, the agency said on Friday.
The drug, a rival to Sanofi-Aventis SA (SASY.PA) and Bristol-Myers Squibb Co's (BMY.N) blockbuster drug Plavix, will include a "black box" warning about the drug's potential for "significant, sometimes fatal, bleeding," the FDA said.
The drug, also known as prasugrel, should also not be used in those with certain bleeding, a history of stroke or an urgent need for surgery, the agency said in a statement. (Reporting by Susan Heavey, editing by Matt Daily)
© Thomson Reuters 2009 All rights reserved
Wall St meets "The Sopranos"
Details of an alleged insider trading ring read like the script of a mobster drama, full of coded nicknames, disposable cell phones and paranoia about informants. But in the end, all of the precautions were for naught. Full Article
